ATE388961T1 - Verfahren zur identifikation von inhibitoren - Google Patents

Verfahren zur identifikation von inhibitoren

Info

Publication number
ATE388961T1
ATE388961T1 AT04775932T AT04775932T ATE388961T1 AT E388961 T1 ATE388961 T1 AT E388961T1 AT 04775932 T AT04775932 T AT 04775932T AT 04775932 T AT04775932 T AT 04775932T AT E388961 T1 ATE388961 T1 AT E388961T1
Authority
AT
Austria
Prior art keywords
apobec3g
vif
degradation
binds
inhibit
Prior art date
Application number
AT04775932T
Other languages
English (en)
Inventor
David Kabat
Mariana Marin
Susan Kozak
Kristine Rose
Original Assignee
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE388961(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Oregon Health & Science filed Critical Univ Oregon Health & Science
Application granted granted Critical
Publication of ATE388961T1 publication Critical patent/ATE388961T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04775932T 2003-05-23 2004-05-03 Verfahren zur identifikation von inhibitoren ATE388961T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47335703P 2003-05-23 2003-05-23

Publications (1)

Publication Number Publication Date
ATE388961T1 true ATE388961T1 (de) 2008-03-15

Family

ID=34272433

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04775932T ATE388961T1 (de) 2003-05-23 2004-05-03 Verfahren zur identifikation von inhibitoren

Country Status (6)

Country Link
US (1) US7220554B2 (de)
EP (1) EP1629003B1 (de)
AT (1) ATE388961T1 (de)
CA (1) CA2525972A1 (de)
DE (1) DE602004012406T2 (de)
WO (1) WO2005024422A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60227069D1 (de) * 2001-02-27 2008-07-24 Univ Rochester VERFAHREN UND ZUSAMMENSETZUNGEN ZUR MODIFIKATION DER BEARBEITUNG VON APOLIPOPROTEIN B-mRNA
EP2116604A1 (de) * 2002-08-05 2009-11-11 University of Rochester Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
GB0228429D0 (en) * 2002-12-05 2003-01-08 Novartis Ag Organic compounds
WO2005004798A2 (en) 2003-06-10 2005-01-20 The J. David Gladstone Institutes Methods for treating lentivirus infections
US20050112555A1 (en) * 2003-09-03 2005-05-26 Smith Harold C. Cytidine deaminase activators, deoxycytidine deaminase activators, Vif antagonists, and methods of screening for molecules thereof
US20050112562A1 (en) * 2003-11-10 2005-05-26 Rigel Pharmaceuticals, Inc. Inhibition of retroviral replication through modulation of the host cell ubiquitylation
WO2005077105A2 (en) * 2004-02-11 2005-08-25 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reduction of hiv-1 replication by a mutant apolipoprotein b mrna editing enzyme-catalytic polypeptide-like 3 g (apobec3g)
US8158770B2 (en) * 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
WO2006065377A2 (en) * 2004-11-02 2006-06-22 The Regents Of The University Of California Methods of treating lentivirus infection
US8841068B2 (en) * 2005-02-11 2014-09-23 University Of Rochester Human immunodeficiency virus antiviral screening assay involving the detection of CEM15 expression
TWI294036B (en) * 2005-02-24 2008-03-01 Tzu Chi Buddhist General Hospital A method for screening compounds against flaviviruses infection by using persistent virus-infected cell systems
WO2006111866A2 (en) * 2005-03-08 2006-10-26 Molmed Spa Hiv vif mutants
KR20090034350A (ko) * 2006-06-23 2009-04-07 바셀 폴리올레핀 이탈리아 에스.알.엘 마그네슘 클로로알콜레이트계 촉매 전구체
US8338089B2 (en) 2006-11-20 2012-12-25 The Johns Hopkins University Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity
US7803582B2 (en) * 2007-03-17 2010-09-28 Hongzhan Xu Recombinant vector and use in gene therapy
WO2008118871A2 (en) * 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Methods of detecting inhibitors of vif-mediated apobec3g degradation and hiv
ATE539155T1 (de) * 2007-08-13 2012-01-15 Nexigen Gmbh Targets und zusammensetzungen zur therapeutischen intervention bei hiv-infektion
US20090075309A1 (en) * 2007-09-06 2009-03-19 Gambhir Sanjiv S Bisdeoxycoelenterazine derivatives, methods of use, and BRET2 systems
US20120271036A1 (en) * 2009-10-29 2012-10-25 University Of Rochester Solution Assay and High Through-Put Screen to Probe Interaction Between Human Cullin-Ring Ligase Complex and HIV-VIF Protein
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
FR2973040B1 (fr) * 2011-03-23 2016-04-15 Centre Nat De La Rech Scient (C N R S) Methode de criblage de composes antiretroviraux et vaccin
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3077417A1 (de) * 2013-12-08 2016-10-12 Peptcell Limited Hiv-antigene und antikörper und zusammensetzungen, verfahren und verwendungen davon
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2023089808A1 (ja) * 2021-11-22 2023-05-25 隆英 河野 ＡＰＯＢＥＣ３Ｇ／Ｖｉｆ結合体形成阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005851A1 (en) 1993-08-20 1995-03-02 St. Luke's-Roosevelt Hospital Center HIV vif-RELATED COMPOSITIONS, AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF
US6360178B1 (en) * 1997-12-09 2002-03-19 Antony Cozart Parsons System and method for locating a disturbance in a power system based upon disturbance power and energy
AU3330700A (en) 1999-03-29 2000-10-16 Tasuku Honjo Novel cytidine deaminase
CA2442909C (en) * 2001-04-06 2011-11-29 Thomas Jefferson University Multimerization of hiv-1 vif protein as a therapeutic target
DK1506288T3 (da) 2002-05-10 2013-07-22 Medical Res Council Aktiveringsinduceret deaminase (aid)
US20040009951A1 (en) * 2002-06-13 2004-01-15 Malim Michael H DNA deamination mediates innate immunity to (retro)viral infection
EP2116604A1 (de) * 2002-08-05 2009-11-11 University of Rochester Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon

Also Published As

Publication number Publication date
WO2005024422A2 (en) 2005-03-17
WO2005024422A3 (en) 2005-06-30
US20040234956A1 (en) 2004-11-25
DE602004012406T2 (de) 2009-04-30
EP1629003B1 (de) 2008-03-12
US7220554B2 (en) 2007-05-22
DE602004012406D1 (de) 2008-04-24
CA2525972A1 (en) 2005-03-17
EP1629003A2 (de) 2006-03-01

Similar Documents

Publication Publication Date Title
ATE388961T1 (de) Verfahren zur identifikation von inhibitoren
Strebel HIV accessory proteins versus host restriction factors
Adedeji et al. Antiviral drugs specific for coronaviruses in preclinical development
EA200801025A1 (ru) Композиция и синтез новых реагентов для ингибирования репликации вич
ATE505475T1 (de) Nukleosidderivate als inhibitoren viraler polymerasen
EA201301284A1 (ru) Способ получения соединений, являющихся ингибиторами вирусной полимеразы и способ получения фармацевтических композиций, а также промежуточные соединения
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
DK1427817T3 (da) Formering af vira i cellekultur
EA200870164A1 (ru) Лечение вирусного гепатита
NO20073396L (no) Farmasoytiske kombinasjoner av en angiotensinreceptorantagonist og en NEP-inhibitor
EA201171174A1 (ru) Ингибиторы репликации вируса гепатита c
BRPI0514372A (pt) inibidores de tiazol de frutose 1, 6-bisfosfatase
EA200700243A1 (ru) Способы лечения гепатита с
EA200970680A1 (ru) N-замещенные производные глицина: ингибиторы гидроксилаз
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
ATE553764T1 (de) Zusammensetzungen und verfahren zur identifizierung von inhibitoren einer retrovirusinfektion
TR201815272T4 (tr) İnfluenza virüs replikasyonu inhibitörleri.
CY1113103T1 (el) Φωσφονικα νουκλεοσιδιων και αναλογα εξ αυτων για την αγωγη των λοιμωξεων-hpv
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
EA200801560A1 (ru) Бифенилкарбоксамиды
ATE486878T1 (de) Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties